TWST: We'd like to begin with a brief historical sketch of Aethlon
Medical and a picture of the things you're doing right now.
Mr. Joyce: We are focused on developing and commercializing the first
medical devices to treat infectious disease. Aethlon was founded in 1998
as a medical device acquisition company, became public in 2000, and
transitioned to developing our Hemopurifier technology as a treatment
for drug and vaccine resistant pathogens in 2001.
TWST: Can you explain your basic science?
Mr. Joyce: The basic science converges the well-established principals
of hemodialysis with the discovery of affinity agents that have the
ability to bind a broad-spectrum of infectious disease targets,
including several biological weapon threats, naturally evolving pandemic
threats such as H5N1 Avian flu, and chronic infectious disease targets
including HIV and Hepatitis-C.
TWST: Can you go a little bit further in describing how your devices
work?
Mr. Joyce: Absolutely. The Hemopurifier is designed to mimic the natural
immune response of clearing viruses and toxins before the occurrence of
cell and organ infection. The cartridge works in conjunction with
portable pumps or can be deployed for use in the global infrastructure
of dialysis machines already in hospitals and clinics. The treatment is
initiated by circulating the patients blood into the Hemopurifier. Once
in the cartridge, the blood travels through thousands of hollow-fibers
whose walls have pores large enough to allow viruses and toxins to be
separated outside of the blood. Once viruses and toxins have been
separated, they are captured by affinity agents that bind directly to
glycoproteins that reside on the surface of envelope viruses in general.
This unique and proprietary mechanism allows us to target all strains of
hard to treat chronic conditions such as HIV, as well as a broad
spectrum of naturally evolving pandemic threats and candidate pathogens
that could be weaponized by man to be bioterror agents.
Tickers included in this excerpt: AEMD
For more information call (212) 952 7433. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
